Results 1 to 10 of about 51,921 (307)

Identification of key genes predicting the efficacy of mepolizumab in the treatment of severe eosinophilic asthma. [PDF]

Sci Rep
Xinmin P, Jinxia C, Fengyuan L.
europepmc   +1 more source

Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma. [PDF]

Antibodies (Basel)
Walsh GM.
europepmc   +1 more source

Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. [PDF]

Eur Respir Rev
Hanania NA, Herth FJF.
europepmc   +1 more source

Eosinophils in Asthma

Tuberculosis and Respiratory Diseases, 1999
openaire   +1 more source

Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study. [PDF]

World Allergy Organ J
Canonica GW, Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Caminati M, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Pelaia G.   +22 more
europepmc   +1 more source

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report. [PDF]

BMC Pulm Med
Drick N, Kaireit TF, Ruwisch J, Schallhorn S, Bauersachs J, Schenk H, Hoeper MM, Witte T, Seeliger B.   +8 more
europepmc   +1 more source

Can Coexisting Allergic Rhinitis in Patients with Severe Eosinophilic Asthma Be a Prognostic Factor for Efficacy of Biological Therapy? Analysis of Eosinophilic Involvement. [PDF]

J Clin Med
Jura-Szołtys E, Glück J, Klimek L, Gawlik R.   +3 more
europepmc   +1 more source

Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE). [PDF]

J Clin Med
Toma CL, Teodorescu G, Mihălţan FD, Frent S, Ali S, Trenchea M, Constantin AA.   +6 more
europepmc   +1 more source

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A 32-Week Evaluation.

Int Arch Allergy Immunol
Özden Ş, Tepetam FM, Bozkurt Y, Terzioğlu Şahin F, Aynacı A, Avcı HF, Dursun M, Demirkol MA, Yıldırım N.   +8 more
europepmc   +1 more source

Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a <i>post hoc</i> analysis of the ANANKE study. [PDF]

ERJ Open Res
Senna G, Brussino L, Aliani M, Altieri E, Bracciale P, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, De Michele F, Del Giacco S, Di Marco F, Malerba L, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Schroeder JW, Vultaggio A, D'Amato M, Caminati M.   +22 more
europepmc   +1 more source